Radioimmunotherapy Market
Radioimmunotherapy Market Study by Ibritumomab, Rituximab, Epratuzumab, Tositumumab, Lintuzumab, Labetuzumab, and Trastuzumab Drugs for Leukemia, Breast Cancer, and Others From 2024 to 2034
Analysis of Radioimmunotherapy Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Radioimmunotherapy Market Outlook (2024 to 2034)
The global radioimmunotherapy market is analyzed to generate revenue worth US$ 1.37 billion in 2024 and is further projected to reach US$ 3.16 billion by 2034-end. Demand is forecasted to rise at an excellent CAGR of 8.7% between 2024 to 2034.
The acceptance rate of radioimmunotherapy is increasing due to the rising incidences of several diseases, especially non-Hodgkin's lymphoma and other blood cancers. Radioimmunotherapy is providing a viable alternative as targeted, particularly for patients with cancer cases who are unresponsive to conventional treatments or have relapsed. The potential of radioimmunotherapy is continuously increasing due to advancements in the creation of monoclonal antibodies, which are essential to the treatment.
The accuracy of radioimmunotherapy is improving with the discovery of new antibodies, improving patient outcomes, and lowering adverse effects. Personalized and targeted cancer therapies are becoming more popular as they are more effective and have fewer adverse effects than conventional chemotherapy and radiation.
North America is estimated to account for 34% portion of the global market share in 2024. This region is holding a leading position due to strong healthcare infrastructure and increasing investment in cancer research. High investment in oncology research and the presence of prominent pharmaceutical companies are also contributing to the market growth in North America. The market in South Asia & Pacific is projected to expand at a noteworthy CAGR of 11.4% during the forecast period due to the rising cancer diagnoses.
Based on drug type, Ibritumomab is evaluated to account for 35.5% portion of the overall revenue in 2024. Because it is effective in treating some non-Hodgkin's lymphoma cases particularly relapsed or refractory cases, Ibritumomab is in high demand. Ibritumomab, used in radioimmunotherapy, combines a monoclonal antibody with a radioactive isotope, allowing it to specifically target and eliminate malignant B cells while minimizing damage to healthy cells.
| Report Attributes | Details |
|---|---|
| Radioimmunotherapy Market Size (2024E) | US$ 1.37 Billion |
| Forecasted Market Value (2034F) | US$ 3.16 Billion |
| Global Market Growth Rate (2024 to 2034) | 8.7% CAGR |
| North America Market Share (2024E) | 34% |
| Western Europe Market Value (2024E) | US$ 311.74 Million |
| South Asia & Pacific Market Growth Rate (2024 to 2034) | 11.4% CAGR |
| Ibritumomab Segment Value (2034F) | US$ 1.19 Billion |
| Non Hodgkin Lymphoma (NHL) Segment Value (2034F) | US$ 1.78 Billion |
| Key Companies Profiled | GlaxoSmoithKlline Plc.; Bayer Healthcare Pharmaceuticals; BioSynthema, Inc.; Molecular Insight Pharmaceuticals; Telix Pharmaceuticals; Spectrum Pharmaceuticals, Inc.; MabVax Therapeutics Holdings, Inc.; Nordic Nanovector, Immunomedics, Inc.; Actinium Pharmaceuticals; NorthStar Medical Technologies; Clarity Pharmaceuticals |
Radioimmunotherapy (RIT) is the combination of radiation therapy and immunotherapy mainly used to treat non-Hodgkin lymphoma for newly diagnosed patients, and the various types of cancers in patients who failed to respond to the chemotherapy treatment.
For instance, according to the National Cancer Institute estimation about 1.81 million cancer cases were found worldwide in 2018. Moreover, in 2020, about 1,806,590 active cases were present in the United States.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Radioimmunotherapy (RIT) Market: Drivers and Restraints
Increasing adoption of targeted therapies and, a rise in adverse complications with radiation therapy are the few propellants of the radioimmunotherapy (RIT) market. The emerging clinical pipeline of radioimmunotherapy and its focus on innovative treatment techniques for enhancing patient outcomes are expected to drive the global market of radioimmunotherapy (RIT) during the forecast period.
The rise in the incidence of cancer cases and increased preference for the intense research and development of cancer therapeutics are expected to drive the global radioimmunotherapy (RIT) market growth. The ambiguities of the lack of evidence-based prognostic factors during the treatment and the high charge for therapy are the factors that are expected to restrain the radioimmunotherapy (RIT) market growth during the forecast period.
Radioimmunotherapy (RIT) Market: Overview
The global radioimmunotherapy (RIT) market manifests considerable growth during the forecast period owing to the rising incidence of cancer among the population. Based on the drug type, Ibritumomab holds the largest market share. Ibritumab, a murine-derived antibody with a short half-life owing to the major advantage of reducing bone marrow toxicity of the attached isotopes was the main reason for the rising preference for the Ibritumab drug over the others.
Based on application, Non-Hodgkin Lymphoma holds the largest market share due to the rise in research and development to treat the disease. Based on the application, leukemia is the dominating segment. Leukemia is radiosensitive, and thus, more likely to respond to radioimmunotherapy. Hospitals govern the end-user segment owing to the availability of better facilities, along with healthcare professionals expected to contribute to the growth of the radioimmunotherapy market.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Radioimmunotherapy (RIT) Market: Region-wise Outlook
North America is evidence to dominate the global radioimmunotherapy (RIT) market during the forecast period owing to the rising prevalence of cancer cases, availability of reimbursement, and increasing healthcare expenditure.
Europe is the second leading region in the radioimmunotherapy (RIT) market due to the growing incidence of cancer, and the rise in the consumption of tobacco and smoke by the increasing population in the region. Globally, around 33% of cancer cases are rising due to the high consumption of tobacco and smoke.
South Asia and East Asia regions witnessed significant growth owing to a rise in funding by regional government bodies, and awareness about early diagnosis is expected to drive the radioimmunotherapy (RIT) market.
Other regions like Latin America and Middle East and Africa are the emerging regions in the radioimmunotherapy (RIT) market.
Radioimmunotherapy (RIT) Market: Leading Key Players
The major players contributing to the radioimmunotherapy (RIT) market are GlaxoSmoithKlline plc, Bayer Healthcare Pharmaceuticals, BioSynthema, Inc., Molecular Insight Pharmaceuticals, Telix Pharmaceuticals, Spectrum Pharmaceuticals, Inc., MabVax Therapeutics Holdings, Inc., Nordic Nanovector, Immunomedics, Inc., Actinium Pharmaceuticals, NorthStar Medical Technologies, Clarity Pharmaceuticals, and others.
The research report on the radioimmunotherapy (RIT) market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on the market provides analysis and information according to market segments such as drug types, applications, and end users.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
The report covers exhaust analysis on
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Europe (Germany, Italy, France, UK, Spain, Russia)
- East Asia (China, Japan, South Korea)
- South Asia (India, ASEAN)
- Oceania (Australia, New Zealand)
- Middle East and Africa (GCC Countries, South Africa, Northern Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators, and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Report Highlights
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint
Segmentation of Radioimmunotherapy Market Research
-
By Drug Type :
- Ibritumomab
- Rituximab
- Epratuzumab
- Tositumumab
- Lintuzumab
- Labetuzumab
- Trastuzumab
-
By Application :
- Non-Hodgkin Lymphoma (NHL)
- Follicular Lymphoma
- Breast Cancer
- Ovarian Cancer
- Osteosarcoma
- Melanoma
- Leukemia
-
By End User :
- Hospitals
- Ambulatory Surgical Centers
- Cancer Research Institutes
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis and Forecast
- 6.1. Drug Type
- 6.2. Application
- 6.3. End User
- 7. Global Market Analysis and Forecast, By Drug Type
- 7.1. Ibritumomab
- 7.2. Rituximab
- 7.3. Epratuzumab
- 7.4. Tositumumab
- 7.5. Lintuzumab
- 7.6. Labetuzumab
- 7.7. Trastuzumab
- 8. Global Market Analysis and Forecast, By Application
- 8.1. Non Hodgkin Lymphoma (NHL)
- 8.2. Follicular Lymphoma
- 8.3. Breast Cancer
- 8.4. Ovarian Cancer
- 8.5. Osteosarcoma
- 8.6. Melanoma
- 8.7. Leukemia
- 8.8. Others
- 9. Global Market Analysis and Forecast, By End User
- 9.1. Hospitals
- 9.2. Ambulatory surgical centers
- 9.3. Cancer research institute
- 10. Global Market Analysis and Forecast, By Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. East Asia
- 10.6. South Asia & Pacific
- 10.7. MEA
- 11. North America Sales Analysis and Forecast, by Key Segments and Countries
- 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries
- 13. Western Europe Sales Analysis and Forecast, by Key Segments and Countries
- 14. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries
- 15. East Asia Sales Analysis and Forecast, by Key Segments and Countries
- 16. South Asia & Pacific Sales Analysis and Forecast, by Key Segments and Countries
- 17. MEA Sales Analysis and Forecast, by Key Segments and Countries
- 18. Sales Forecast by Drug Type, Application, and End User for 30 Countries
- 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 20. Company Profile
- 20.1. GlaxoSmithKline plc
- 20.2. Bayer Healthcare Pharmaceuticals
- 20.3. BioSynthema, Inc.
- 20.4. Molecular Insight Pharmaceuticals
- 20.5. Telix Pharmaceuticals
- 20.6. Spectrum Pharmaceuticals, Inc.
- 20.7. MabVax Therapeutics Holdings, Inc.
- 20.8. Nordic Nanovector
- 20.9. Immunomedics, Inc.
- 20.10. Actinium Pharmaceuticals
- 20.11. NorthStar Medical Technologies
- 20.12. Clarity Pharmaceuticals
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market US$ Mn Forecast by Region
Table 2: Global Market US$ Mn Forecast by Drug Type
Table 3: Global Market US$ Mn Forecast by Application
Table 4: Global Market US$ Mn Forecast by End User
Table 5: North America Market US$ Mn Forecast by Country
Table 6: North America Market US$ Mn Forecast by Drug Type
Table 7: North America Market US$ Mn Forecast by Application
Table 8: North America Market US$ Mn Forecast by End User
Table 9: Latin America Market US$ Mn Forecast by Country
Table 10: Latin America Market US$ Mn Forecast by Drug Type
Table 11: Latin America Market US$ Mn Forecast by Application
Table 12: Latin America Market US$ Mn Forecast by End User
Table 13: Western Europe Market US$ Mn Forecast by Country
Table 14: Western Europe Market US$ Mn Forecast by Drug Type
Table 15: Western Europe Market US$ Mn Forecast by Application
Table 16: Western Europe Market US$ Mn Forecast by End User
Table 17: Eastern Europe Market US$ Mn Forecast by Country
Table 18: Eastern Europe Market US$ Mn Forecast by Drug Type
Table 19: Eastern Europe Market US$ Mn Forecast by Application
Table 20: Eastern Europe Market US$ Mn Forecast by End User
Table 21: East Asia Market US$ Mn Forecast by Country
Table 22: East Asia Market US$ Mn Forecast by Drug Type
Table 23: East Asia Market US$ Mn Forecast by Application
Table 24: East Asia Market US$ Mn Forecast by End User
Table 25: South Asia & Pacific Market US$ Mn Forecast by Country
Table 26: South Asia & Pacific Market US$ Mn Forecast by Drug Type
Table 27: South Asia & Pacific Market US$ Mn Forecast by Application
Table 28: South Asia & Pacific Market US$ Mn Forecast by End User
Table 29: MEA Market US$ Mn Forecast by Country
Table 30: MEA Market US$ Mn Forecast by Drug Type
Table 31: MEA Market US$ Mn Forecast by Application
Table 32: MEA Market US$ Mn Forecast by End User
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Type
Figure 2: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Application
Figure 3: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 4: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Region
Figure 5: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Type
Figure 6: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Application
Figure 7: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 8: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 9: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Type
Figure 10: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Application
Figure 11: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 12: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 13: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Type
Figure 14: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Application
Figure 15: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 16: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 17: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Type
Figure 18: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Application
Figure 19: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 20: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 21: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Type
Figure 22: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Application
Figure 23: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 24: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 25: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Type
Figure 26: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Application
Figure 27: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 28: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 29: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Type
Figure 30: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Application
Figure 31: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 32: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is driving the demand outlook for the Radioimmunotherapy Market?
Increasing adoption of targeted are driving the radioimmunotherapy (RIT) market.
Where will the growth spearhead in the Radioimmunotherapy market?
North America is expected to witness the highest growth over the forecast period.
Which are the top players in the market?
Key players are GlaxoSmoithKlline plc, Bayer Healthcare Pharmaceuticals, BioSynthema, Inc., and Telix Pharmaceuticals.
Radioimmunotherapy Market